Journal of Psychopharmacology
June 26, 2021
Emma I Kopra, Valeria Mondelli, Carmine M. Pariante et al.
89 citations
Background: Ketamine is a novel rapid-acting antidepressant with high efficacy in treatment-resistant patients. Its exact therapeutic mechanisms of action are unclear; however, in recent years its anti-inflammatory properties and subsequent downstream effects on tryptophan (TRP) metabolism have sparked research interest. Aim: This systematic review examined the effect of ketamine on...
Pharmacy
June 25, 2021
Linda Xing Yu Liu, Marina Golts, Virginia Fernandes
2 citations
The impact of depression is well described in the literature, and it is most prominent in patients who have trialed multiple treatments. Treatment-resistant depression (TRD) is particularly debilitating, and it is associated with significant morbidity and mortality. Despite this, there seems to be therapeutic inertia in adopting novel therapies in current practice. Ketamine is an...
The International Journal of Neuropsychopharmacology
June 25, 2021
Jolien K E Veraart, Sanne Y Smith-Apeldoorn, I. M. Bakker et al.
44 citations
Abstract Background The use of ketamine for depression has increased rapidly in the past decades. Ketamine is often prescribed as an add-on to other drugs used in psychiatric patients, but clear information on drug-drug interactions is lacking. With this review, we aim to provide an overview of the pharmacodynamic interactions between ketamine and mood stabilizers, benzodiazepines, monoamine...
Royal Society Open Science
June 23, 2021
Thomas F. Varley, Vanessa Denny, Olaf Sporns et al.
Research has found that the vividness of conscious experience is related to brain dynamics. Despite both being anaesthetics, propofol and ketamine produce different subjective states: we explore the different effects of these two anaesthetics on the structure of dynamic attractors reconstructed from electrophysiological activity recorded from cerebral cortex of two macaques. We used two...
Frontiers in Behavioral Neuroscience
June 23, 2021
Alina Wilkowska, Łukasz P. Szałach, Wiesław Jerzy Cubała
32 citations
According to the WHO, major depressive disorder is the leading cause of disability worldwide, and it is a major contributor to the overall global burden of disease. The pathophysiology of this common and chronic disease is still not completely understood. The gut microbiome is an increasingly recognized environmental factor that can have a role in depression, acting through the...
Health Psychology Research
June 22, 2021
Sahar Derakhshanian, Maxine Zhou, Alexander Rath et al.
21 citations
PURPOSE OF REVIEW: This is a comprehensive review of the literature regarding the use of ketamine as a treatment for treatment-resistant depression (TRD). It covers the epidemiology, risk factors, pathophysiology, and current treatment modalities regarding Major Depressive Disorder (MDD) and TRD. It provides background on the mechanism of action of ketamine, its history, current approved and...
Neuropharmacology
June 19, 2021
Ariandra Sartim, Jade Marques, Kennia Silveira et al.
BACKGROUND AND PURPOSE Although useful as a rapid-acting antidepressant drug, ketamine is known to induce psychotomimetic effects, which may interfere with its therapeutic use. Cannabidiol (CBD) is a non-psychostimulant compound from Cannabis sativa, which has shown promising antidepressant effects without inducing hyperlocomotion. AMPA receptor activation is involved in the antidepressant...
Journal of Sleep Research
June 16, 2021
Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz et al.
28 citations
Summary Sleep disturbances are commonly reported in patients with treatment‐resistant depression (TRD). Available data have shown that intravenous (IV) ketamine is an effective treatment for patients with TRD and growing data suggest ketamine may improve overall sleep architecture. In the present study, we evaluated whether changes in sleep symptoms mediated the anti‐depressive and/or...
medRxiv Preprint Server
June 13, 2021
Rui Du, Kun Niu, Guofang Lu et al.
preprint
The aim of this systematic review and meta-analysis was to examine the efficacy, anti-effect of ketamine (intervention) for post-traumatic stress disorder (PTSD) patients during analgesia proceeding and mental illness treatment methods, in comparison with control (midazolam, opioid, saline or placebo). The bibliographic databases Cochrane, Embase, Pubmed and Web of Science were searched from...
PAIN Reports
June 3, 2021
Eunice Y. Hahm, Shubham Chamadia, J. Locascio et al.
6 citations
Ketamine-induced dissociation and analgesia are independent and robust to general anesthesia neural circuit alterations, suggesting that ketamine can be refined into a targeted pain therapeutic. Abstract Introduction: Ketamine, an anesthetic adjunct, is routinely administered as part of a balanced general anesthetic technique. We recently showed that the acute analgesic and dissociation...